The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

insulin icodec), a long-acting basal insulin analogue for type 1 and type 2 diabetes that is the first drug in the class to offer once-weekly subcutaneous administration, rather than daily dosing.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.

After hours: 7:59:17 pm GMT-5 ...